Source: http://www.google.com/patents/US7776919?dq=5708422
Timestamp: 2014-10-01 09:12:38
Document Index: 14837797

Matched Legal Cases: ['Application No. 02', 'Application No. 2002', 'Application No. 2', 'Application No. 02', 'Application No. 02', 'Application No. 02', 'Application No. 2002', 'Application No. 02', 'Application No. 2', 'Application No. 2', 'Application No. 2007203289']

Patent US7776919 - modulators of the interaction between the receptor for advanced glycated end ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign in<nobr>Advanced Patent Search</nobr>PatentsThis invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end...http://www.google.com/patents/US7776919?utm_source=gb-gplus-sharePatent US7776919 - modulators of the interaction between the receptor for advanced glycated end products; 3-(4-Benzyloxyphenyl)propionic Acid 2,4- Di-(3-Diethylamino-1-propoxy)aniline Amide; acute and chronic inflammation; diabetic late complications; Alzheimer's disease, erectile dysfunction; metastasisAdvanced Patent SearchPublication numberUS7776919 B2Publication typeGrantApplication numberUS 12/019,045Publication dateAug 17, 2010Filing dateJan 24, 2008Priority dateMar 5, 2001Also published asCA2440042A1, CA2440042C, CN1494425A, CN1494425B, EP1377295A2, EP1377295A4, US7423177, US20020193432, US20080119512, US20100286197, WO2002070473A2, WO2002070473A3Publication number019045, 12019045, US 7776919 B2, US 7776919B2, US-B2-7776919, US7776919 B2, US7776919B2InventorsAdnan M. M. Mjalli, Robert C. Andrews, Ramesh Gopalaswamy, Christopher L. WysongOriginal AssigneeTransTech Pharm, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (41), Non-Patent Citations (105), Referenced by (3), Classifications (62), Legal Events (4) External Links: USPTO, USPTO Assignment, Espacenetmodulators of the interaction between the receptor for advanced glycated end products; 3-(4-Benzyloxyphenyl)propionic Acid 2,4- Di-(3-Diethylamino-1-propoxy)aniline Amide; acute and chronic inflammation; diabetic late complications; Alzheimer's disease, erectile dysfunction; metastasisUS 7776919 B2Abstract This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4166452Jan 5, 1978Sep 4, 1979Generales Constantine D J JrApparatus for testing human responses to stimuliUS4265874Apr 25, 1980May 5, 1981Alza CorporationMethod of delivering drug with aid of effervescent activity generated in environment of useUS4356108Dec 20, 1979Oct 26, 1982The Mead CorporationEmulsifying hydrophobic phase containing oil and hydrophilic phase containing amine saltUS4873313Apr 18, 1985Oct 10, 1989Beckman Research Institute Of City Of HopeSpecific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigensUS5153226Jul 30, 1990Oct 6, 1992Warner-Lambert CompanyAcat inhibitors for treating hypocholesterolemiaUS5202424Aug 23, 1991Apr 13, 1993The Rockefeller UniversityMesangial cell-derived receptors for advanced glycosylation endproducts and uses thereofUS5585344Aug 23, 1991Dec 17, 1996The Rockefeller UniversityLiver-derived receptors for advanced glycosylation endproducts and uses thereofUS5688653Jun 27, 1996Nov 18, 1997The Picower Institute For Medical Research3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use thereforUS5795907Aug 9, 1994Aug 18, 1998James Black Foundation LimitedGastin and CCK receptor ligandsUS5864018Apr 16, 1996Jan 26, 1999Schering AktiengesellschaftAntibodies to advanced glycosylation end-product receptor polypeptides and uses thereforUS5922770Jul 17, 1997Jul 13, 1999Novo Nordisk A/SNovel compounds that stimulate the release of growth hormone from the pituitaryUS5939526Sep 20, 1995Aug 17, 1999Ludwig Institute For Cancer ResearchIsolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereofUS6100098Feb 17, 1998Aug 8, 2000Mcgill UniversityDiagnosis of arthritis, atherosclerosis, amyloidosis, diabetes and crohn's disease in humans; incubating support coated advanced glycation end product antibody with a sample, detecting antibodies, presence of abtibody indicates defectUS6613801 *Mar 5, 2001Sep 2, 2003Transtech Pharma, Inc.Method for the synthesis of compounds of formula I and their uses thereofUS6677299Nov 5, 2001Jan 13, 2004The Trustee Of Columbia University In The City Of New YorkMethod to increase cerebral blood flow in amyloid angiopathyUS6825164Aug 14, 2000Nov 30, 2004The Trustees Of Columbia University In The City Of New YorkMethod to increase cerebral blood flow in amyloid angiopathyUS7067554 *Jul 1, 2003Jun 27, 2006Transtech Pharma, Inc.Method for the synthesis of compounds of formula I and their uses thereofUS20040097407Jul 1, 2003May 20, 2004Mjalli Adnan M.M.Method for the synthesis of compounds of formula I and their uses thereofUS20050026811May 20, 2004Feb 3, 2005Mjalli Adnan M. M.antagonists for the receptor for advanced glycated endproducts(RAGE), used for treatment of Alzheimer's diseaseCA2379695A1May 25, 2001Dec 6, 2001Trans Tech PharmaCompounds for modulating the rage receptorFR1176918A Title not availableGB2005674A Title not availableJPH0751550A Title not availableWO1995009838A1Sep 20, 1994Apr 13, 1995Michael R AngelastroINHIBITORS OF β-AMYLOID PROTEIN PRODUCTIONWO1995035279A1May 19, 1995Dec 28, 1995Merrell Pharma IncSubstituted alkyldiamine derivatives and their use as tachykinin antagonistsWO1996032385A1Mar 11, 1996Oct 17, 1996Hoechst Marion Roussel IncNovel substituted piperazine derivatives having tachykinin receptor antagonists activityWO1997022618A1Dec 20, 1996Jun 26, 1997Vertex PharmaINHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYMEWO1997026913A1Jan 21, 1997Jul 31, 1997Univ ColumbiaA POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDEWO1997039121A1Apr 11, 1997Oct 23, 1997Schering AgAdvanced glycosylation end-product receptor peptides and uses thereforWO1997039125A1Apr 11, 1997Oct 23, 1997Schering AgAntibodies against the advanced glycosylation end-product receptor and uses thereofWO1998022138A1Nov 12, 1997May 28, 1998Univ ColumbiaMethod for treating symptoms of diabetesWO1998033492A1Feb 5, 1998Aug 6, 1998Fox Chase Cancer CenterCompounds and methods for therapeutic intervention in preventing diabetic complicationsWO1999007402A1Aug 5, 1998Feb 18, 1999Univ ColumbiaMETHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTSWO1999018987A1Oct 9, 1998Apr 22, 1999Univ ColumbiaLigand binding site of rage and uses thereofWO1999025690A2Nov 9, 1998May 27, 1999Univ Kansas Medical CenterAdvanced glycation end-product intermediaries and post-amadori inhibitionWO1999050230A1Mar 31, 1999Oct 7, 1999Govinda R BhisettiInhibitors of serine proteases, particularly hepatitis c virus ns3 proteaseWO1999054485A1Apr 16, 1999Oct 28, 1999Univ ColumbiaA method for inhibiting tumor invasion or spreading in a subjectWO2000020458A1Oct 5, 1999Apr 13, 2000Univ ColumbiaMethods for determining whether a compound is capable of inhibiting the interaction of a peptide with rageWO2000020621A1Oct 6, 1999Apr 13, 2000Ann Marie SchmidtExtracellular novel rage binding protein (en-rage) and uses thereofWO2001012598A2Aug 11, 2000Feb 22, 2001Ann Marie SchmidtMETHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOFWO2001092210A1May 25, 2001Dec 6, 2001Trans Tech PharmaCompounds for modulating the rage receptor* Cited by examinerNon-Patent CitationsReference1Albercio et al., "Coupling Reagents and Activation" Methods in Enzymology 289:104-126, Academic Press, San Diego (1997).2Barton et al., "In Protection of N-H Bonds and NR3" Protective Groups in Organic Chemistry, J.F.W. McOmie, ED, Plenum Press, New York, NY (1973).3Berge et al., "Pharmaceutical Salts" Journal of Pharmaceutical Sciences, vol. 66, pp. 1-19, (1977).4Birkofer, L. et al., "Synthese von beta-Aminoaldehyden," Chemishce Berichte, 1961, 94:216-220.5Birkofer, L. et al., "Synthese von β-Aminoaldehyden," Chemishce Berichte, 1961, 94:216-220.6Blacker, D. et al., "Reliability and Validity of NINCDS-ADRDA Criteria for Alzheimer's Disease," Arch. Neurol., 1994, 51:1198-1204.7Chitaley et al., "Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway" Nature Medicine, vol. 44, pp. 119-122, (2002).8Database CAPLUS an STN (Columbus OH, USA) No. 131:267043 Abstract of Tsukita et al., "Aminocarboxylic acids, selectin inhibitors containing them, and their uses" (1999).9Database CAPLUS on STN (Columbus OH, USA) No. 105:60932 Abstract of Digenis at al., "Peptidyl Carbamates Incorporating Amino Acid Isosteres as Novel Elastase Inhibitors" (1986).10Database CAPLUS on STN (Columbus OH, USA) No. 112:199010 Abstract of Pirkle et al., "Separation of the enantiomers of N-protected alpha-amino acids as anilide and 3, 5-dimethylanilide derivatives" (1990).11Database CAPLUS on STN (Columbus OH, USA) No. 112:199010 Abstract of Pirkle et al., "Separation of the enantiomers of N-protected α-amino acids as anilide and 3, 5-dimethylanilide derivatives" (1990).12Database CAPLUS on STN (Columbus OH, USA) No. 114:228476 Abstract for Vidubiriene et al., "Synthesis and study of derivatives of 3-alkylamino)-2-(methylthio)carbaxylla acids" (1990).13Database CAPLUS on STN (Columbus OH, USA) No. 116:58986 Abstract of Hamada et al., Preparation of anilide derivatives for determination of enzymes (1992).14Database CAPLUS on STN (Columbus OH, USA) No. 122:106460 Abstract of Sivanandaiah et al., "Synthesis of peptides mediated by KOBI" (1995).15Database CAPLUS on STN (Columbus OH, USA) No. 92:41660 Abstract of Frappier et al., "Peptidic Alkaloids, X. Approach for the Synthesis of Peptidic Alkaloids. 1. Reactivity of N-toylsulfonylaziridines towards reactive nucleophiles" (1978).16Database CAPLUS on STN (Columbus, OH, USA No. 92:41524 Abstract of Dobrev, et al. "Addition of N.N-disubstituted amides to N-benzoyl diphenyl kelimine in the presence of lithium amide in liquid ammonia" (1978).17Deane, R. et al., "RAGE Mediates Amyloid-Beta Peptide Transport Across the Blood-Brain Barrier and Accumulation in Brain," Nature Medicine, 2003, 9:907-913.18Degenhardt et al., "Chemical Modification of Proteins by Methylglyoxal" Cellular and Molecular Biology, vol. 44, pp. 1139-1145, (1998).19Digenis et al., "Peptidyl Carbamates Incorporating Amino Acid Isosteres as Novel Elastase inhibitors" Journal of Medicinal Chemistry, vol. 29, pp. 1468-1476, (1986).20Dobrev et al., Khimicheski Fakultet (1978), Volume Date 1975-1976, 70, Pt. 1, 201-7, CAS online abstract retrieved Apr. 16, 2007 from STN, Columbus, OH.21Dyer et al., "Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging" Journal of Clinical Investigation, vol., 91, pp. 2463-2369, (1993).22Dyer et al., "Formation of Pentosidine during NonenzymatIc Browning of Proteins by Glucose" Journal of Biological Chemistry, vol., 266, pp. 11654-11660 (1990).23Final Office Action for U.S. Appl. No. 11/362,993 mailed Apr. 4, 2008.24Frappier et al., "Peptidic Alkaloids. X. Approach for the Synthesis of Peptidic Alkaloids. 1. Reactivity of N-toylsulfonylazirldlnes towards reactive nucleophiles" Tetrahedron, vol. 34, pp. 2911-2916, (1978) (Language-French).25Frappier et al., "Peptidic Alkaloids. X. Approach for the Synthesis of Peptidic Alkaloids. 1. Reactivity of N-toylsulfonylazirldlnes towards reactive nucleophiles" Tetrahedron, vol. 34, pp. 2911-2916, (1978) (Language�French).26Girouard, H. et al., "Neurovascular Coupling in the Normal Brain and in Hypertension, Stroke, and Alzheimer Disease," J. Appl. Physiol., 2006, 100:328-335.27GRAF, Justus Liebigs Annalen der Chemie, 1963, pp. 111-157.28Greene et al., "Protection for Amino Group" Protective Groups in Organic Synthesis, John Wiley and Sons, New York, NY, Chapter 7 (1981).29Hammes, et al., "Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidatlon product N�-(Carboxymethyl) Ly7sine Independently of Glycohaemoglobin Concentrations" Diabetologia, vol. 42, pp. 603-607, (1999).30Hoffman et al., "RAGE Mediates a Novel Prainflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides" Cell, vol., 97, pp. 889-901, (1999).31Horl et al., "The Receptor for Advanced Glycation End Products (RAGE) is a Cellular Binding Site for Amphoterin" Journal of Biological Chemistry, vol., 270, pp. 25752-25761, (1995).32Huttunen et al., "Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways" Journal of Biological Chemistry, vol., 274, pp. 19919-19924 , (1999).33International Search Report for PCT application PCT/US02/06707 dated Nov. 5, 2002.34International Search Report for related PCT application, PCT/US01/17251 dated Aug. 14, 2001.35Kumar et al, "RAGE at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloidbeta1-40 Petptide" Neuroscience Program, 141-#255.19 (2000).36Kumar et al, "RAGE at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloidβ1-40 Petptide" Neuroscience Program, 141-#255.19 (2000).37Leder et al., "v-HA-ras Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid" Proceedings of the National Academy of Sciences of the United States of America, vol. 87, pp. 9178-9182, (1990).38Li et al., "Characterization and Functional Analysis of the Promoter for RAGE, the Receptor for Advanced Glycation End Products" Journal of Biological Chemistry, vol., 272, pp. 16496-16506, (1997).39Li et al., "Sp1-Binding Elements in the Promoter of RAG Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells." Journal of Biological Chemistry, vol. 272, pp. 16498-16506, (1997).40Lugering et al., "The Myeloic Related Protein MRP8/14 (27E10 Antigen)-Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function" European Journal of Clinical Investigation, vol. 25, pp. 659-664 (1995).41Lugering et al., "The Myeloic Related Protein MRP8/14 (27E10 Antigen)�Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function" European Journal of Clinical Investigation, vol. 25, pp. 659-664 (1995).42Mackic, J. et al., "Human Blood-Brain Barrier Receptors for Alzheimer's Amyloid-Beta 1-40," J. Clin. Invest., 1998, 102:734-743.43McKenzie, A. et al., "beta-Amino-beta-phenylpropiophenone," J. Chem. Soc. Trans., 1921, 119:69-76.44McKenzie, A. et al., "β-Amino-β-phenylpropiophenone," J. Chem. Soc. Trans., 1921, 119:69-76.45McKhann, G. et al., "Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group Under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," Neurology, 1984, 34:939-944.46Miyata et al., "Beta2-Micro globulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis" Journal of Clinical Investigation, vol. 92, pp. 1243-1252 (1993).47Miyata et al., "The Receptor for Advanced Glycation End Products (RAGE) is a Central Mediator of the Interaction of AGE-Beta2 Micro globulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway" Journal of Clinical investigation, vol. 98. pp. 1088-1094 (1995).48Miyata et al., "Beta2�Micro globulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis" Journal of Clinical Investigation, vol. 92, pp. 1243-1252 (1993).49Neeper et al., "Cloning and Expression of a Cell Surface Receptor for Advance Glycosylation End Products of Proteins" Journal of Biologic Chemistry, vol. 267, pp. 14996-15004 (1992).50Non-Final Office Action for U.S. Appl. No. 11/362,993 mailed Nov. 14, 2008.51Non-Final Office Action for U.S. Appl. No. 11/511,163 mailed Jul. 22, 2008.52Notice of Allowance dated Aug. 6, 2009 corresponding to U.S. Appl. No. 11/511,163.53Notice of Allowance mailed Mar. 22, 2005 corresponding to U.S. Appl. No. 10/091,759.54Notice of Allowance mailed Oct. 17, 2007 corresponding to U.S. Appl. No. 10/091,759.55Office Action dated Aug. 21, 2009 corresponding to CN Patent Application No. 02 8 05994.8.56Office Action dated Aug. 26, 2008 corresponding to JP Patent Application No. 2002-569794.57Office Action dated Dec. 20, 2006 corresponding to CA Patent Application No. 2,440,042.58Office Action dated Feb. 18, 2005 corresponding to CN Patent Application No. 02 8 05994.8.59Office Action dated Feb. 20, 2009 corresponding to CN Patent Application No. 02 8 05994.8.60Office Action dated Jan. 25, 2008 corresponding to CN Patent Application No. 02 8 05994.8.61Office Action dated Jun. 16, 2009 corresponding to JP Patent Application No. 2002-569794.62Office Action dated Jun. 6, 2008 corresponding to CN Patent Application No. 02 8 05994.8.63Office Action dated Nov. 13, 2008 corresponding to CA Patent Application No. 2,440,042.64Office Action dated Nov. 22, 2007 corresponding to CA Patent Application No. 2,440,042.65Office Action dated Nov. 26, 2008 corresponding to AU Patent Application No. 2007203289.66Office Action mailed Apr. 10, 2003 corresponding to U.S. Appl. No. 10/091,759.67Office Action mailed Apr. 20, 2007 corresponding to U.S. Appl. No. 10/091,759.68Office Action mailed Aug. 19, 2009 corresponding to U.S. Appl. No. 11/946,641.69Office Action mailed Aug. 9, 2007 corresponding to U.S. Appl. No. 10/091,759.70Office Action mailed Feb. 13, 2009 for U.S. Appl. No. 11/511,163.71Office Action mailed Jan. 25, 2005 corresponding to U.S. Appl. No. 10/091,759.72Office Action mailed Jul. 19, 2006 corresponding to U.S. Appl. No. 10/091,759.73Office Action mailed Jul. 29, 2003 corresponding to U.S. Appl. No. 10/091,759.74Office Action mailed Mar. 25, 2004 corresponding to U.S. Appl. No. 10/091,759.75Office Action mailed May 28, 2010 corresponding to U.S. Appl. No. 11/946,641.76Office Action mailed Oct. 16, 2007 corresponding to U.S. Appl. No. 10/091,759.77Office Action mailed Sep. 24, 2004 corresponding to U.S. Appl. No. 10/091,759.78Parkkinen et al., "Amphoterin, the 30 -kDa Protein in a Family of HMG1-Type Polypeptides" Journal of Biological Chemistry, vol. 268, pp. 19725-19738 (1993).79Rammes et al., "Myeloid-Related Protein (MRP) 8 and MRP 14, Calcium-Binding Proteins of the S100 Family, are Secreted by Activated Monocytes via a Novel, Tubulin-Dependent Pathway", Journal of Biological Chemistry, vol. 272, pp. 9496-9502 (1997).80Ranginwala, N. et al., "Clinical Criteria for the Diagnosis of Alzheimer Disease: Still Good After All These Years," Am. J. Geriatr. Psychiatry, 2008, 16:384-388.81Rauvala et al., "Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons" Journal of Biological Chemistry, vol. 262, pp. 16625-16635 (1987).82Reddy et al., "N -(Carboxymethyl) Lysine is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins" Biochemistry, vol. 34, pp. 10572-10878 (1995).83Reddy et al., "N �(Carboxymethyl) Lysine is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins" Biochemistry, vol. 34, pp. 10572-10878 (1995).84Schafer et al., "The S100 Family of EF-Hand Calcium-Binding Proteins: Functions an Pathology" TIBS, vol. 21, pp. 134-140 (1996).85Schleicher et al., "Increased Accumulation of the GlycoxidatIon Product N-(Carboxymethyl) Lysine in Human Tissues in Diabetes and Aging" Journal of Clinical Investigation, vol. 99, pp. 457-488 (1997).86Schmidt et al., "The Dark side of Glucose", Nature of Medicine, vol. 1, pp. 1002-1004 (1995).87Schmidt et al., "The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications:" Supplement to Circulation vol. 96, #194 (1987).88Snowdon, D., "Healthy Aging and Dementia: Findings from the Nun Study," Ann Intern Med., 2003, 139:450-454.89Taguchi et al., "Blockade of RAGE-Amphoterin Signaling Suppresses Tumor Growth and Metastases" Nature, vol. 405, pp. 354-360 (2000).90Tanaka et al., "The Receptor for Advanced Glycation End Protocols is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-a through Nuclear Fact- kB, and 17 beta-Estradoll through Sp-1 in Human Vascular Endothelial Cells" Journal of Biological Chemistry, vol. 275, pp. 25781-25790 (2000).91Tanaka et al., "The Receptor for Advanced Glycation End Protocols is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-a through Nuclear Fact- kB, and 17 β-Estradoll through Sp-1 in Human Vascular Endothelial Cells" Journal of Biological Chemistry, vol. 275, pp. 25781-25790 (2000).92Teillet et al., "Food Restriction Prevents Advanced Glycation End Product Accumulation and Retards Kidney Aging in Lean Rats" Journal of the American Society of Nephrology, vol. 11, pp. 1486-1497 (2000).93Vidugiriene et al., "Synthesis and study of derivatives of 3-alkylamino)-2-(methylthio)carboxylic acids" Chemija, vol. 2, pp. 101-106, (1990) (Language-Russian).94Vidugiriene et al., "Synthesis and study of derivatives of 3-alkylamino)-2-(methylthio)carboxylic acids" Chemija, vol. 2, pp. 101-106, (1990) (Language�Russian).95Vlassara et al., "Advanced Glycation End-Products and Atherosclerosis" The Finnish Medical Society Duodecim, Ann. Med., vol. 28, pp. 416-426 (1998).96Wautier et al., "Receptor-Mediated Endothelial Cell Dysfunction in Diabetic Vasculophathy: Soluble Receptor for Advanced Glycation End Products Blocks Hyper permeability in Diabetic Rats" Journal of Clinical Investigation, vol. 97, pp. 238-243 (1996).97Yan et al., "Amyloid-beta Peptide-Receptor for Advanced Glycation Endproducts interaction Elicitis Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease" Proceedings of the National Academy of Sciences of the United States of America, vol. 94, pp. 5298-5301 (1997).98Yan et al., "An Intracellular Protein that Binds Amyloid-beta Peptide and mediates Neurotoxicity in Alzheimer's Disease" Nature, vol. 389, 689-695 (1897).99Yan et al., "Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation Endproducts with their Receptors Binding Proteins" Journal of Biological Chemistry, vol. 269, pp. 9889-9897 (1994).100Yan et al., "RAGE and Amyloid-beta Peptide Neurotoxicity in Alzheimer's Disease" Nature, vol. 382, pp. 585-591 (1996).101Yan et al., "Receptor-Dependent Cell Stress and Amylold Accumulation in Systemic Amyloidosis" Nature Medicine, vol. 5, pp. 643-651 (2000).102Yan et al., "Amyloid-β Peptide�Receptor for Advanced Glycation Endproducts interaction Elicitis Neuronal Expression of Macrophage�Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease" Proceedings of the National Academy of Sciences of the United States of America, vol. 94, pp. 5298-5301 (1997).103Yan et al., "An Intracellular Protein that Binds Amyloid-β Peptide and mediates Neurotoxicity in Alzheimer's Disease" Nature, vol. 389, 689-695 (1897).104Yan et al., "RAGE and Amyloid-β Peptide Neurotoxicity in Alzheimer's Disease" Nature, vol. 382, pp. 585-591 (1996).105Zimmer et al., "The S100 Protein Family: History, Function, and Expression" Brain Research Bulletin, vol. 37, pp. 417-429 (1995).Referenced byCiting PatentFiling datePublication dateApplicantTitleUS8431575Feb 15, 2011Apr 30, 2013Transtech Pharma, Inc.Phenyl-heteroaryl derivatives and methods of use thereofUS8580833Sep 23, 2010Nov 12, 2013Transtech Pharma, Inc.Substituted imidazole derivatives and methods of use thereofUS8741900Feb 21, 2013Jun 3, 2014Transtech Pharma, LlcPhenyl-heteroaryl derivatives and methods of use thereofClassifications U.S. Classification514/613, 564/200, 564/211, 564/194, 564/202International ClassificationA61P43/00, A61K31/4164, A61P27/02, A61K31/401, A61P3/10, A61P35/04, A61P13/12, A61P35/00, A61P7/00, A61K31/4465, C07D233/60, A61P15/10, A61K31/4462, A61K31/445, A61P25/28, A61K31/167, A61K31/351, C07C271/18, A61P9/10, A61P29/00, A61K31/472, C07D233/90, A61K31/27, C07C233/00, C07D521/00, C07D207/16, C07C235/38, C07D217/26, C07D211/34, A01N37/18, C07C271/22, C07C237/20, C07D309/04, C07C237/00, C07C235/00Cooperative ClassificationC07D309/04, C07C237/20, C07D207/16, C07C271/22, C07D217/26, C07D249/08, C07D233/56, C07D211/34, C07C2103/18, C07C2101/08, C07D231/12, C07C235/38European ClassificationC07D309/04, C07D249/08, C07C271/22, C07D211/34, C07D207/16, C07D233/56, C07D217/26, C07C235/38, C07C237/20, C07D231/12Legal EventsDateCodeEventDescriptionApr 7, 2014ASAssignmentFree format text: NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0803;ASSIGNOR:M&F TTP HOLDINGS LLC;REEL/FRAME:032621/0860Owner name: TRANSTECH PHARMA, LLC, NORTH CAROLINAEffective date: 20140328Mar 28, 2014REMIMaintenance fee reminder mailedAug 9, 2013ASAssignmentOwner name: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDIEffective date: 20130809Free format text: SECURITY AGREEMENT;ASSIGNOR:TRANSTECH PHARMA, INC.;REEL/FRAME:030982/0803Jan 29, 2008ASAssignmentOwner name: TRANSTECH PHARMA, INC., NORTH CAROLINAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MJALLI, ADNAN M.M.;ANDREWS, ROBERT C.;GOPALASWAMY, RAMESH;AND OTHERS;REEL/FRAME:020430/0735Effective date: 20020305RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google